| Literature DB >> 28595345 |
Andreas Müssigbrodt1, Helge Knopp1, Elena Efimova1, Alexander Weber1, Livio Bertagnolli1, Sebastian Hilbert1, Jedrzej Kosiuk1, Borislav Dinov1, Kerstin Bode1, Simon Kircher1, Nikolaos Dagres1, Sergio Richter1, Philipp Sommer1, Daniela Husser1, Andreas Bollmann1, Gerhard Hindricks1, Arash Arya1.
Abstract
Aims: This study aimed to assess the impact of supraventricular tachycardia (SVT) on long-term results of radiofrequency catheter ablation therapy of ventricular tachycardia (VT) in a large cohort of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Methods and results: Supraventricular tachycardia occurrence has been studied in patients from our ARVD/C registry (70 patients, 48 male, age 53.2 ± 14.0, 45 patients (64.3%) with previous VT ablation). SVT were diagnosed in 26 of 70 patients (37.1%). Atrial fibrillation (AF) was the most frequent atrial arrhythmia, diagnosed in 17 patients (24.3%). In univariate analysis advanced age, clinical symptoms of heart failure, enlarged right atrium, diagnosis of significant tricuspid regurgitation (TR), and inappropriate implantable cardioverters-defibrillators therapy were associated with SVT. In binary logistic regression analysis only heart failure: hazard ratio (HR) 10.89, 95% confidence interval (95% CI) 1.08-109.96 (P = 0.043) and significant TR: HR 4.79, 95% CI 1.35-16.33 (P = 0.015) remained associated with SVT. In patients with previous VT ablation Cox multiple regression survival analysis revealed older age (≥53 years): HR 4.63, 95% CI 1.51-14.24 (P = 0.008) and SVT: HR 3.01, 95% CI 1.15-7.89 (P = 0.025) as predictors for VT recurrence during the follow-up.Entities:
Mesh:
Year: 2018 PMID: 28595345 DOI: 10.1093/europace/eux179
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.214